Abbott Laboratories (ABT) 44.95 $ABT TMVR Market -

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbott Laboratories (ABT) 44.95 $ABT

TMVR Market - Medtronic, Abbott Laboratories, Inc & Edward Lifesciences Corporation Lead Transcatheter Mitral Valve Replacement Industry
PR Newswire Europe - Wed Aug 03, 11:45AM CDT
PUNE, India, August 3, 2016 /PRNewswire/ --
ABT: 44.95 (-0.12), MDT: 86.67 (-0.97)

Abbott Unveils Alinity(TM), its Unified Family of Innovative Next-Generation Diagnostics Systems
PR Newswire Europe - Tue Aug 02, 9:00AM CDT
Abbott announced today the introduction of Alinity(TM), its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.
ABT: 44.95 (-0.12)

Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.21 (+1.49), ABT: 44.95 (-0.12), ICPT: 172.59 (+2.12), EXEL: 9.39 (+0.24)

Watch for Shares of Abbott Laboratories (ABT) to Approach Resistance at $45.57
Comtex SmarTrend(R) - Mon Aug 01, 9:13AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $44.71 and have already reached the first level of resistance at $45.16. Should the shares continue to rise, the resistance pivots of $45.57 and $46.43 will be of interest.
ABT: 44.95 (-0.12)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)

What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVLS: 4.83 (+0.02), CYTR: 0.61 (+0.04), CEMP: 22.20 (+2.04), ACUR: 1.88 (+0.04), NVS: 82.40 (-0.56)

Bank of America trade offers a 9% return in 204 days, or find similar option trades on Ariad Pharmaceuticals, US Steel, CyberArk Software, and Abbott Laboratories
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, ARIA, BAC, CYBR, and X.
ABT: 44.95 (-0.12), CYBR: 56.15 (+1.25), BAC: 14.48 (+0.35), ARIA: 9.93 (+0.21), X: 26.20 (+0.51)

Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.05% Rise
Comtex SmarTrend(R) - Thu Jul 28, 11:54AM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.93 to a high of $45.16. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $43.90 on volume of 9.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.95 (-0.12)

Abbott Laboratories (ABT) Breaks Through Resistance at $43.97
Comtex SmarTrend(R) - Thu Jul 28, 8:42AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $43.60 today and has reached the first level of resistance at $43.97. Analysts will be watching for a cross of the next upside pivot targets of $44.26 and $44.92.
ABT: 44.95 (-0.12)

Q2 Earnings Season Coming Up Roses
Mark Vickery - ZACKS - Wed Jul 20, 5:12AM CDT
Morgan Stanley, Abbott Labs and Halliburton all beat earnings expectations before the opening bell today.
ABT: 44.95 (-0.12), EBAY: 30.95 (+0.16), QCOM: 61.01 (+0.41), HAL: 42.94 (+0.88), INTC: 34.25 (-0.31), MSFT: 56.97 (+0.39), UAL: 44.90 (+0.50), MS: 28.42 (+0.42)

Abbott Labs (ABT) Q2 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
Abbott Laboratories (ABT) is scheduled to report second-quarter 2016 results before the opening bell on Jul 20.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVS: 82.40 (-0.56)

Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
CNW Group - Mon Jul 18, 7:30AM CDT
Medical Cannabis' biggest strength continues to be science as research and development drives sector forward with more consumers opting for marijuana over traditional treatment methods. Investors continue to pour millions of dollars into the newest studies and development of Medical Marijuana Applications as more states push towards legalization.
ABT: 44.95 (-0.12), INSY: 17.85 (+2.65), GWPH: 95.02 (+0.95), PFE: 35.29 (-1.10)

Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:24PM CDT
Alere Inc. (ALR) lowered revenue estimate for the year that ended on Dec 31, 2015 and also offered some Q1 figures.
BSX: 23.84 (-0.33), ABT: 44.95 (-0.12), ALR: 37.24 (+0.65), NUVA: 62.76 (+0.13)

Why is Alere Inc. (ALR) up Today?
Afrasiab Mian - Zacks Investment Research - Fri Jul 15, 2:52PM CDT
Alere Inc. (ALR) is up 10.5% in afternoon trading on Friday after analysts saw an increased likelihood that the company's $5.8 billion acquisition by Abbott Laboratories (ABT) would close.
ABT: 44.95 (-0.12), ALR: 37.24 (+0.65)

Eli Lilly, Boehringer Collaborate for Metastatic Breast Cancer
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:25AM CDT
Eli Lilly (LLY) inked a clinical trial collaboration with Boehringer for the evaluation of abemaciclib-BI 836845 combination for metastatic breast cancer.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), INVA: 13.01 (+0.17), LLY: 82.72 (-0.60)

Learn how to target a 20% return on Gilead Sciences, or get option-trade ideas on Aetna, Exelixis, Priceline and Abbott Laboratories or any stock you choose
PR Newswire - Thu Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, AET, EXEL, GILD, and PCLN.
ABT: 44.95 (-0.12), GILD: 80.09 (+0.52), AET: 116.86 (+1.15), PCLN: 1,371.14 (+25.76), EXEL: 9.39 (+0.24)

Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 8:30AM CDT
Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical
ABT: 44.95 (-0.12), SNN: 33.20 (-0.28), JNJ: 123.90 (-0.95), MDT: 86.67 (-0.97), STJ: 83.53 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 375

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

GreenPower Motor Company Aims for Enhanced Growth by Delisting

Updated Category News Views 218

GreenPower Motor Company Announces Delisting Decision GreenPower Motor Company Inc. (NASDAQ: GP) is making a significant move in its growth strategy. The company, which is renowned for manufacturing and distributing all-electric vehicles tailored for medium and heavy-duty applications, has decided to voluntarily delist its shares from the TSX Venture Exchange (the...

Continue Reading
VEON Announces Q4 2024 Trading Update Conference Details

Updated Category News Views 264

VEON Announces Q4 2024 Trading Update Conference Details Dubai – VEON Ltd. (NASDAQ: VEON), a prominent digital operator, has confirmed the upcoming release of significant financial information regarding its fourth quarter and full year ending December 31, 2024. This update will occur around 10:00 GST (2:00 EST) on March 20, 2025. In addition to the financial update,...

Continue Reading
Netcapital's Revenue Fraud Scandal Hits Investor Confidence

Updated Category News Views 206

The Rise and Fall of Netcapital: A Troubling Drop Netcapital Inc. (NASDAQ: NCPL) has found itself in hot water with investors after revelations of a wild scheme to fluff up its revenue figures. It’s like watching a house of cards crumble — and investors are left holding the bag. From December 15, 2021, through September 3, 2026, a slew of misinformation allegedly...

Continue Reading
Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return

Updated Category News Views 394

Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return This Memorial Day weekend marks a significant moment in history as the San Francisco East Bay welcomes back a hero after eight decades. The community prepares for a heartfelt homecoming for 2nd Lt. Thomas V. Kelly Jr., who served valiantly as a bombardier during World War II. A Journey Through History Born in...

Continue Reading
TOMY's Zoids Ultrasaurus: Gun for Nostalgia and Growth

Updated Category News Views 28

Unlocking the Power of Nostalgia with TOMY's Ultrasaurus Nostalgia isn't just an emotion; it's a powerful force that can drive sales like nobody's business, and TOMY Company knows this well. They're rolling out the big guns—literally—by adding the animated series' beloved Gravity Cannon to their new AZ-17DX Ultrasaurus model. How's that for a hook? The Gravity Cannon...

Continue Reading